bromocriptine has been researched along with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 7 (26.92) | 18.7374 |
| 1990's | 14 (53.85) | 18.2507 |
| 2000's | 4 (15.38) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (3.85) | 2.80 |
| Authors | Studies |
|---|---|
| Bédard, PJ; Di Paolo, T; Gagnon, C | 1 |
| Bédard, PJ; Di Paolo, T; Rouillard, C | 1 |
| Brown, A; Dali, H; Neumeyer, JL; Pihan, G; Szabo, S | 1 |
| Bédard, P; Boucher, R; Daigle, M; Di Paolo, T | 1 |
| Boyce, S; Jenner, P; Marsden, CD | 1 |
| Bédard, PJ; Boucher, R; Di Paolo, T; Falardeau, P | 1 |
| Williams, A | 1 |
| Cohen, O; Globus, M; Melamed, E; Rosenthal, J; Uzzan, A | 1 |
| Jonsson, G; Mefford, I; Schultz, W; Studer, A; Sundström, E | 1 |
| Gsell, W; Lange, KW; Naumann, M; Oestreicher, E; Rausch, WD; Riederer, P | 1 |
| Bankiewicz, KS; Belluzzi, JD; Domino, EF; May, JM; McAfee, DA | 1 |
| Archer, T; Fredriksson, A; Plaznik, A; Sundström, E | 1 |
| Fukuda, T; Irifune, M; Nomoto, M | 1 |
| Hadjiconstantinou, M; Hubble, JP; Neff, NH; Sylvia, CP; Wemlinger, TA | 1 |
| Krupina, NA; Kryzhanovskiĭ, GN; Orlova, IN | 1 |
| Arai, N; Fukuyama, J; Isaji, M; Kuno, S; Miyata, H; Mizuta, E | 1 |
| Fukuda, T; Tanaka, J; Watabe, K | 1 |
| Kitamura, Y; Kohno, Y; Nakazawa, M; Nomura, Y | 1 |
| Banerji, T; Jenner, P; Marsden, CD; Pearce, RK | 1 |
| Mohanakumar, KP; Muralikrishnan, D | 1 |
| Iordanskaia, TE; Krupina, NA; Kryzhanovskiĭ, GN; Orlova, IN | 2 |
| Bar-Gad, I; Bergman, H; Goldberg, JA; Heimer, G | 1 |
| Mitsumoto, Y; Mori, A; Moriizumi, T; Nakai, M; Ohashi, S | 1 |
| Chacun, H; Farinotti, R; Fernandez, C; Lacomblez, L; Milane, A; Vautier, S | 1 |
| Huang, X; Mailman, RB; Yang, Y | 1 |
2 review(s) available for bromocriptine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Receptor changes during chronic dopaminergic stimulation.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Brain Diseases; Bromocriptine; Dopamine; Humans; Hydroxydopamines; Injections, Intraperitoneal; Levodopa; Neurotransmitter Agents; Oxidopamine; Parkinson Disease; Pergolide; Primates; Pyridines; Receptors, Dopamine; Substance Withdrawal Syndrome | 1988 |
Neuroprotection by dopamine agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Aging; Animals; Bromocriptine; Dopamine Agonists; Humans; Neuroprotective Agents; Neurotoxins; Parkinson Disease; Pergolide | 1994 |
24 other study(ies) available for bromocriptine and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
| Article | Year |
|---|---|
Effect of chronic treatment of MPTP monkeys with dopamine D-1 and/or D-2 receptor agonists.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Autoradiography; Brain; Bromocriptine; Carbidopa; Catecholamines; Dopamine Agents; Female; Levodopa; Macaca fascicularis; Receptors, Dopamine; Spiperone | 1990 |
Effects of chronic treatment of MPTP monkeys with bromocriptine alone or in combination with SKF 38393.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; 3,4-Dihydroxyphenylacetic Acid; Animals; Antiparkinson Agents; Brain; Brain Chemistry; Bromocriptine; Dopamine; Female; Homovanillic Acid; Kinetics; Levodopa; Macaca fascicularis; Motor Activity; MPTP Poisoning; Parkinson Disease, Secondary; Receptors, Dopamine; Spiperone | 1990 |
Duodenal ulcer induced by MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine).
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Amylases; Animals; Bicarbonates; Bromocriptine; Dose-Response Relationship, Drug; Duodenal Ulcer; Duodenum; Ergolines; Female; Gastric Acid; Gastric Emptying; Gastrointestinal Motility; Monoamine Oxidase Inhibitors; Pancreas; Pyridines; Rats; Rats, Inbred Strains; Trypsin | 1985 |
Long-term effects of MPTP on central and peripheral catecholamine and indoleamine concentrations in monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 3,4-Dihydroxyphenylacetic Acid; Animals; Biogenic Amines; Brain; Bromocriptine; Catecholamines; Chromatography, High Pressure Liquid; Female; Homovanillic Acid; Hydroxyindoleacetic Acid; Levodopa; Macaca fascicularis; Parkinson Disease, Secondary; Prolactin; Pyridines | 1986 |
Chronic treatment with L-DOPA, but not bromocriptine induces dyskinesia in MPTP-parkinsonian monkeys. Correlation with [3H]spiperone binding.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Binding Sites; Bromocriptine; Butyrophenones; Female; Kinetics; Levodopa; Macaca fascicularis; Movement Disorders; Parkinson Disease, Secondary; Pyridines; Spiperone; Time Factors | 1986 |
MPTP toxicity: clinical features.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Bromocriptine; California; Chemical Industry; District of Columbia; Female; Humans; Levodopa; Male; Occupational Diseases; Parkinson Disease, Secondary; Pyridines | 1986 |
Suppression of MPTP-induced dopaminergic neurotoxicity in mice by nomifensine and L-DOPA.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Apomorphine; Bromocriptine; Corpus Striatum; Dopamine; Haloperidol; Levodopa; Male; Mice; Mice, Inbred C57BL; Nomifensine; Pyridines | 1985 |
Deficits in behavioral initiation and execution processes in monkeys with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Biogenic Amines; Brain Chemistry; Bromocriptine; Female; Levodopa; Macaca fascicularis; Male; Motor Activity; Movement; Parkinson Disease, Secondary; Pyridines | 1985 |
N-0923, a selective dopamine D2 receptor agonist, is efficacious in rat and monkey models of Parkinson's disease.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Disease Models, Animal; Dominance, Cerebral; Dopamine Agents; Female; Injections, Intramuscular; Macaca nemestrina; Male; Oxazines; Oxidopamine; Parkinson Disease, Secondary; Prolactin; Rats; Rats, Sprague-Dawley; Receptors, Dopamine D2; Stereotyped Behavior; Substantia Nigra; Tetrahydronaphthalenes; Thiophenes | 1994 |
Effects of D1 and D2 agonists on spontaneous motor activity in MPTP treated mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Animals; Behavior, Animal; Brain; Bromocriptine; Drug Combinations; Locomotion; Male; Mice; Mice, Inbred C57BL; Motor Activity; Receptors, Dopamine D1; Receptors, Dopamine D2 | 1994 |
Effects of talipexole on motor behavior in normal and MPTP-treated common marmosets.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Azepines; Bromocriptine; Callithrix; Dopamine Agents; Female; Injections, Intravenous; Male; Motor Activity; Parkinson Disease, Secondary; Receptors, Dopamine D2 | 1993 |
Aromatic L-amino acid decarboxylase activity of mouse striatum is modulated via dopamine receptors.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Aromatic-L-Amino-Acid Decarboxylases; Benzazepines; Bromocriptine; Corpus Striatum; Cycloheximide; Dopamine Antagonists; Haloperidol; Kinetics; Levodopa; Male; Mice; Pyridoxal Phosphate; Receptors, Dopamine; Reserpine; Sulpiride; Time Factors | 1993 |
[The effect of parlodel on development of depressive syndrome in rats, caused by administering 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Depressive Disorder; Disease Models, Animal; Dopamine Agonists; Drinking Behavior; Male; MPTP Poisoning; Rats; Rats, Wistar; Receptors, Dopamine D2 | 1995 |
Differential effects of three dopamine receptor agonists in MPTP-treated monkeys.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Cabergoline; Dopamine Agonists; Dose-Response Relationship, Drug; Ergolines; Macaca fascicularis; Parkinson Disease, Secondary; Pergolide | 1995 |
Effects of bromocriptine and/or L-DOPA on neurons in substantia nigra of MPTP-treated C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Cell Count; Levodopa; Mice; Mice, Inbred C57BL; Substantia Nigra | 1996 |
Inhibitory effects of talipexole and pramipexole on MPTP-induced dopamine reduction in the striatum of C57BL/6N mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; 1-Methyl-4-phenylpyridinium; 3,4-Dihydroxyphenylacetic Acid; Animals; Azepines; Benzothiazoles; Bromocriptine; Dopamine; Dopamine Agents; Dopamine Agonists; Homovanillic Acid; In Vitro Techniques; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; Neostriatum; Pramipexole; Synaptosomes; Thiazoles | 1997 |
De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Bromocriptine; Callithrix; Dose-Response Relationship, Drug; Drug Administration Schedule; Dyskinesia, Drug-Induced; Female; Indoles; Levodopa; Male; Motor Skills; Neurologic Examination; Parkinson Disease, Secondary; Receptors, Dopamine D2 | 1998 |
Neuroprotection by bromocriptine against 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced neurotoxicity in mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Behavior, Animal; Bromocriptine; Dopamine Agents; Dopamine Agonists; Hydroxyl Radical; Mice; Mice, Inbred BALB C; Motor Neurons; Motor Skills Disorders; Substantia Nigra | 1998 |
[Effect of parlodel on sleep-wakefulness cycle parameters in rats with experimental MPTP-induced depressive syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Bromocriptine; Depressive Disorder; Dopamine Agonists; Male; Rats; Rats, Wistar; Sleep, REM; Syndrome; Wakefulness | 1999 |
[Effect of parlodel on the electrical activity of the rat brain during experimental depressive syndrome].
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antidepressive Agents; Brain; Bromocriptine; Caudate Nucleus; Depressive Disorder; Dopamine Agents; Dopamine Agonists; Electroencephalography; Hippocampus; Male; Putamen; Rats; Rats, Wistar; Syndrome | 2000 |
Dopamine replacement therapy reverses abnormal synchronization of pallidal neurons in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of parkinsonism.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Action Potentials; Animals; Antiparkinson Agents; Bromocriptine; Carbidopa; Chlorocebus aethiops; Disease Models, Animal; Dopamine; Dopamine Agonists; Drug Therapy, Combination; Electrodes, Implanted; Female; Globus Pallidus; Levodopa; Neurons; Organic Chemicals; Parkinsonian Disorders | 2002 |
Neural mechanisms underlying motor dysfunction as detected by the tail suspension test in MPTP-treated C57BL/6 mice.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Analysis of Variance; Animals; Behavior, Animal; Blotting, Western; Brain Chemistry; Bromocriptine; Corpus Striatum; Dopamine; Dopamine Agents; Dopamine Agonists; Dopamine Plasma Membrane Transport Proteins; Dose-Response Relationship, Drug; Drug Interactions; Hindlimb Suspension; Immobility Response, Tonic; Immunohistochemistry; Levodopa; Male; Membrane Glycoproteins; Membrane Transport Proteins; Mice; Mice, Inbred C57BL; Monoamine Oxidase Inhibitors; Motor Activity; Nerve Tissue Proteins; Selegiline; Time Factors; Tyrosine 3-Monooxygenase | 2005 |
Role of two efflux proteins, ABCB1 and ABCG2 in blood-brain barrier transport of bromocriptine in a murine model of MPTP-induced dopaminergic degeneration.
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Blood-Brain Barrier; Blotting, Western; Brain; Bromocriptine; Disease Models, Animal; Gene Expression Regulation; Injections, Intraperitoneal; Male; Mice; Mice, Inbred C57BL; MPTP Poisoning; Parkinson Disease; Tissue Distribution | 2009 |
D
Topics: 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine; Animals; Antiparkinson Agents; Brain; Bromocriptine; Chlorocebus aethiops; Disease Models, Animal; Dopamine Agonists; Levodopa; Male; Motor Activity; Parkinsonian Disorders; Phenanthridines; Receptors, Dopamine D1; Receptors, Dopamine D2 | 2021 |